Combination therapies have become a cornerstone of modern psychiatry, and with them comes a quiet but critical challenge: how do manufacturers prove that every tablet contains exactly the right amount of each active ingredient? A research team in Gujarat, India, has now delivered a practical answer for one of the most interesting mood-disorder combinations on the market. In a study published in Discover Chemistry, Divya Solanki and Zarna Dedania describe a validated reverse-phase high-performance liquid chromatography (RP-HPLC) method that can quantify escitalopram oxalate and bupropion hydrochloride at the same time, in a single run, using a single detection wavelength. The work may sound like routine analytical chemistry, but it underpins the quality control of a medicine taken by people battling depression and anxiety, where even small deviations in dose can matter.
The two drugs involved work in strikingly different ways. Escitalopram oxalate belongs to the selective serotonin reuptake inhibitor (SSRI) family, a class that raises serotonin levels in the brain by blocking its reabsorption, thereby strengthening serotonergic signaling. It is widely prescribed for depression and anxiety because of its high tolerability and selectivity. Bupropion hydrochloride, by contrast, is an atypical antidepressant classified as a norepinephrine–dopamine reuptake inhibitor, or NDRI. By preventing the reuptake of norepinephrine and dopamine, it boosts extracellular levels of these monoamine neurotransmitters and increases noradrenergic and dopaminergic neurotransmission, ultimately raising postsynaptic neuronal activity. The fixed-dose combination of the two was approved in April 2017 and has since been used to manage mood disorders, offering clinicians a way to target multiple neurotransmitter systems at once.
Measuring both compounds in one tablet, however, is not trivial. The two molecules differ in polarity, concentration ratio, and chemical behavior, and a synthetic tablet typically contains a large excess of bupropion relative to escitalopram. In the new method, the researchers dissolved a quantity of synthetic mixture equivalent to 10 milligrams of escitalopram and 150 milligrams of bupropion in methanol, sonicated it for 15 to 20 minutes to ensure complete extraction, filtered the solution through a 0.45-micrometer membrane, and diluted it to yield a final sample containing 1 microgram per milliliter of escitalopram and 15 micrograms per milliliter of bupropion. That 1:15 ratio is a demanding test for any chromatographic method, because the detector must remain linear across very different concentration ranges for the two analytes.
The chromatographic conditions the team settled on are elegantly simple. Separation was achieved on a C18 column measuring 250 by 4.6 millimeters with 5-micrometer particles, using a mobile phase of acetonitrile and phosphate buffer at pH 3, adjusted with orthophosphoric acid, in a 75:25 volume ratio. The system ran under isocratic elution, meaning the solvent composition stays constant throughout the run, at a flow rate of 1.0 milliliter per minute with a 10-microliter injection volume and detection at 233 nanometers using a photodiode array detector. The column temperature was held at 30 degrees Celsius. Under these conditions, escitalopram eluted first, at about 4.2 minutes, followed by bupropion at about 7.7 minutes. The order makes physical sense: the more polar escitalopram has a stronger affinity for the polar mobile phase and spends less time interacting with the non-polar stationary phase, while the less polar bupropion lingers longer on the hydrophobic C18 surface before washing off.
Reaching that clean separation took systematic optimization. The researchers experimented with different solvents, pH levels, and solvent compositions before landing on the acidic acetonitrile–buffer blend. Ultraviolet spectra of both drugs were recorded between 200 and 400 nanometers to choose a wavelength at which both compounds absorb strongly enough for simultaneous detection, and 233 nanometers emerged as the best compromise. The resulting chromatograms showed well-resolved, symmetrical peaks without significant tailing, and system suitability testing confirmed healthy values for resolution, tailing factor, and theoretical plates, the classic metrics chromatographers use to judge whether a system is performing properly before trusting any data it produces.
Validation followed the international ICH Q2(R1) guideline, the industry standard for analytical procedure validation. Linearity was demonstrated for escitalopram across 1 to 6 micrograms per milliliter and for bupropion across 15 to 90 micrograms per milliliter, with correlation coefficients of 0.999 in both cases, meaning the detector response rose almost perfectly in proportion to concentration. Accuracy, assessed through recovery experiments, ranged from 98.51 to 100.33 percent for escitalopram and 99.05 to 100.23 percent for bupropion, figures comfortably within the narrow windows regulators expect. Precision was evaluated as repeatability, intraday, and interday variability expressed as relative standard deviation, and all values came in below 2 percent, indicating the method produces consistent results regardless of when or how the measurements are made within a day or across days.
The method also proved sensitive enough for its purpose. Limits of detection, calculated using the ICH equations LOD = 3.3σ/S and LOQ = 10σ/S, where σ is the standard deviation of the response and S the slope of the calibration curve, came out at 0.101 micrograms per milliliter for escitalopram and 1.188 micrograms per milliliter for bupropion. The corresponding limits of quantification were 0.308 and 3.602 micrograms per milliliter, respectively. Specificity testing added another layer of confidence: when blank solutions were analyzed, no interfering peaks appeared at the retention times of either drug, showing that common tablet excipients would not distort the results. Robustness and ruggedness studies, in which chromatographic conditions were deliberately varied, confirmed that retention times and peak areas held steady, meaning the method tolerates small everyday fluctuations in a quality-control laboratory.
When the team applied the method to a synthetic mixture containing 10 milligrams of escitalopram and 150 milligrams of bupropion, the assay recovered 99.98 percent of the escitalopram and 99.94 percent of the bupropion. That near-perfect recovery, combined with the confirmation that additives in the mixture did not disrupt the analysis, demonstrates that the approach is ready for real-world formulation testing. The authors note that the method offers simple chromatographic conditions, rapid analysis, and simultaneous estimation of both drugs at a single wavelength, a combination that translates directly into lower costs and faster turnaround times for pharmaceutical quality-control labs that must analyze thousands of samples.
Why does this matter beyond the laboratory bench? Fixed-dose combination antidepressants sit at the intersection of pharmacology and manufacturing, and every batch that reaches patients depends on validated analytical methods like this one. The literature already contains numerous chromatographic techniques for bupropion and escitalopram individually or paired with other drugs such as clonazepam, etizolam, naltrexone, or aripiprazole, but each new approved combination demands its own validated method tuned to the specific ratio and properties of the drugs involved. By providing a straightforward, reproducible RP-HPLC procedure validated to ICH standards for the escitalopram–bupropion pair, Solanki and Dedania have given manufacturers and regulators a practical tool for routine quality control. It is a reminder that behind every psychiatric prescription lies a web of unglamorous but essential chemistry, ensuring that the pill in the bottle delivers precisely what the label promises.
Subject of Research: Development and validation of an RP-HPLC method for simultaneous quantification of escitalopram oxalate and bupropion hydrochloride in pharmaceutical formulations
Article Title: RP-HPLC method for the simultaneous estimation of escitalopram oxalate and bupropion hydrochloride used for treatment of mood disorder
Article References: RP-HPLC method for the simultaneous estimation of escitalopram oxalate and bupropion hydrochloride used for treatment of mood disorder. (n.d.). https://doi.org/10.1007/s44371-026-01025-5
Image Credits: AI Generated
DOI: 10.1007/s44371-026-01025-5
Keywords: RP-HPLC, escitalopram oxalate, bupropion hydrochloride, method validation, ICH guidelines, antidepressants, mood disorders, pharmaceutical analysis, quality control, chromatography, SSRI, NDRI
News Source: Bethany Barker. (October 12, 2026). New HPLC Method Simultaneously Measures Two Antidepressants in Combination Pills. Scienmag.
